Category: Market Commentary

Impact of fourth-quarter results of 2021 on Lumen Technologies, Inc. (LUMN) stock price?

Lumen Technologies, Inc. (LUMN) stock price has declined by 4.34% in the current market. At the time of writing, LUMN stock was trading around $10.36. Recently, Lumen Technologies, Inc. (LUMN) declared its fourth-quarter results. The company reported a free cash flow of $776 million for Q4 2021. The EBIDTA and net income came around $2.088 billion and $508 billion, respectively. Resultantly, LUMN’s diluted EPS was $0.50. In addition, the company’s net debt was reduced by $1.5 million during the quarter. In contrast to 2020, LUMN has done well during 2021. The company’s total revenue dropped from $20.72 million to $19.68

Market Commentary

Organon& Co. (OGN) Stock Slumping in Premarket, Here’s the Reason

Organon& Co. (OGN), a science-based pharmaceutical company, has declined 13.21% in the premarket trading session and consequently is trading at $28.74 at the time of the writing. During Friday’s regular trading session, the stock gained an increase of 0.61% and closed the day at $33.12. The plunge in aftermarket could be attributed to the Kentucky Retirement System’s insurance trust fund announcement of selling out the Organon during the Q4 of 2021. Let’s discuss some recent developments related to ORN stock. OGN Subsidiary Designating Women’s Day On 2nd February, OGN announced that its subsidiary Organon Canada has designated International Women’s Day,

Market Commentary

Vinco Ventures, Inc. (BBIG) Stock Plunging, Here’s the Reason

Vinco Ventures, Inc. (BBIG), a consumer product research and development, manufacturing, sales, and fulfillment company, has plunged 7.12% during the premarket trading session. Consequently, the stock is trading at $3.65 at the time of the writing. On Thursday, BBIG closed the day at $3.93 after sliding by 13.25% during the regular trading session. The decline is coming in the aftermath of five consecutive days of gain by the stock, which saw it moving from $2.31 to $5.49. Let’s discuss some recent developments related to the stock. Cryptyde Spinoff by BBIG On the 12th of January, BBIG stock rose 23% during

Market Commentary

Evofem Biosciences, Inc. (EVFM) Stock Declining After a Hefty Wednesday, Here’s Why

 Evofem Biosciences, Inc. (EVFM), a biopharmaceutical company, has dropped 6.26% during the premarket trading session. Consequently, the stock is trading at $0.457 at the time of the writing. The decline could be due to the profit-taking factor after the stock rallied by 22.86% during Wednesday’s regular trading session and closed the day at $0.4875. The surge came as the company announced record net sales in the fourth quarter of 2021. Q4 2021 Preliminary Results On Wednesday, EVFM announced the strong preliminary results for the fourth quarter of the fiscal year 2022. The company said that it had achieved net product sales of

Market Commentary

RISE Education Cayman Ltd. (REDU) Stock Sliding in Aftermarket, Here’s the Reason

RISE Education Cayman Ltd. (REDU), a company that provides junior English language training services through its subsidiaries, has declined 4.50% during aftermarket trading session and consequently is trading at $0.50 at the time of the writing. The decline could be attributed to the receipt of the NASDAQ notice for non-compliance. On Tuesday, REDU stock closed the day at $0.53 after gaining an increase of 2.56% during the regular trading session. Why REDU Declining? In the late hours of Tuesday, REDU announced that on the 11th of January, the company received the notice from the Listing Qualifications Department of Nasdaq Stock Market that

Market Commentary

VYNE Therapeutics Inc. (VYNE) had a Bearish Spell, Here’s Why

VYNE Therapeutics Inc. (VYNE), a pharmaceutical company, has surged 7.7% in aftermarket trading session and consequently is trading at $0.74 at the time of the writing. On Monday, VYNE closed the day at $0.6871 after plummeting by 12.53% during regular trading hours. The massive slide was attributable to the divestment of topical minocycline assets. Why VYNE Slid? On Thursday, VYNE announced that it had sold its Molecule Stabilizing Technology franchise to Journey Medical Corporation. The sale also includes the AMZEEQ® (minocycline) topical foam, 4%, ZILXI® (minocycline) topical foam, 1.5%, and VYNE’s pipeline combination product FCD105. The move aligns with the strategic plan

Market Commentary

Salarius Pharmaceuticals, Inc. (SLRX) Stock Declining Despite No Negative News

Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company, has plunged 7.77% in the premarket trading session. As a result, SLRX stock is trading at $0.45 at the time of the writing. The slide has come despite a positive development for the company in the form of expansion in the oncology pipeline. On Thursday, the stock closed the day at $0.49 after slightly declining by 0.93% during regular trading hours. SLRX Agreement With DeuteRx, On Thursday, SLRX entered into a definitive agreement with DeuteRx, LLC. The agreement was meant for the acquisition of an oral, small molecule targeted protein degradation portfolio. The acquisition

Market Commentary

Lumen Technologies, Inc. (LUMN) Stock Declining in Aftermarket, Here’s Why

 Lumen Technologies, Inc. (LUMN), a facilities-based technology and communications company has declined by 4.82% in aftermarket trading session and consequently is trading at $12.65 at the time of the writing. On Wednesday, LUMN closed the day at $13.29 after declining by 0.37% during regular trading hours. The decline has come after the analysts rated the stock as a sell, causing a huge volume of short selling. Let’s discuss some recent developments related to the stock. When LUMN Would Release Q4 2021 Results? On the 5th of January, LUMN announced that it would release its quarterly results for the fourth quarter of the

Market Commentary

MedAvail Holdings, Inc. (MDVL) Stock Suring in Aftermarket, Here’s the Cause

MedAvail Holdings, Inc. (MDVL), a technology-enabled pharmacy company, has surged by 12% in aftermarket trading session and consequently is trading at $1.40 at the time of the writing. The increase has come in the wake of management changes in the company as well as the announcement of preliminary fourth-quarter 2021 and full year 2021 results. On Tuesday, MDVL closed the day at $1.25 after a slight increase of 0.81% during the mid-day session. Management Changes in MDVL In the late hours of Tuesday, MDVL announced that Mark Doerr, RPh has joined the company in the role of Chief Executive Officer. The appointment

Market Commentary

Veru Inc. (VERU) Stock Having Worthwhile Times in Aftermarket, Here’s the Reason

Veru Inc. (VERU), an oncology biopharmaceutical company, has gained an increase of 5.99% in aftermarket trading session. As a result, VERU stock is trading at $5.66 at the time of the writing. The increase could be attributed to the FDA grant of fast track designation for one of Veru’s products. On Monday, VERU closed the day at $5.34 after declining 2.20% during the regular trading session. Why VERU Increasing? On Monday, VERU announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm. Enobosarm is a selective androgen